RxDoctor Payments Data

Victor Owusu Yaw, MD

Neurology · Danville, VANPI 1669518205

Payments from drug & device makers

$21,370in general payments, 2019–2025

Across 1,269 payments — averaging $16.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$2K
  • AbbVie$2K
  • Neurocrine Biosciences, Inc.$2K
  • Acadia Pharmaceuticals Inc$1K
  • Novartis$1K
  • Teva Pharmaceuticals USA, Inc.$853
  • plus $12K from 50 others

What the payments were for

  • Food & beverage$21,20899%
  • Education$1621%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biogen132$2,258
AbbVie(2 entities)143$1,785
Neurocrine Biosciences, Inc.96$1,633
Acadia Pharmaceuticals Inc117$1,410
Novartis66$1,278
Teva Pharmaceuticals USA, Inc.49$853
UCB, Inc.31$789
EMD Serono, Inc.45$760
Lundbeck LLC36$758
Sunovion Pharmaceuticals Inc.37$667
SK Life Science, Inc.31$658
Amneal Pharmaceuticals LLC49$636
AstraZeneca(2 entities)31$609
Lilly USA, LLC33$553
Eisai Inc.25$527
Amgen(2 entities)29$516
Pfizer40$510
Bristol Myers Squibb31$496
Sumitomo Pharma America, Inc.26$436
Otsuka America Pharmaceutical, Inc.21$330
Mallinckrodt Hospital Products Inc.15$306
Greenwich Biosciences, Inc.15$245
Adamas Pharmaceuticals, Inc.11$208
Neurelis, Inc.8$200
Biohaven Pharmaceuticals, Inc.9$199
TG Therapeutics, Inc.9$199
Supernus Pharmaceuticals, Inc.15$198
Biohaven Pharmaceutical Holding Company Ltd.11$195
Impel Pharmaceuticals Inc.10$167
Argenx US, Inc.7$158
Jazz Pharmaceuticals Inc.9$154
Upsher-smith Laboratories LLC7$150
Corium, LLC7$134
Avanir Pharmaceuticals, Inc.13$121
Philips North America LLC5$119
Novo Nordisk1$105
Vanda Pharmaceuticals Inc.5$103
Banner Life Sciences, LLC4$96
Tanabe Pharma America, Inc.5$95
Genentech USA, Inc.5$90
Kyowa Kirin, Inc.4$76
E.r. Squibb & Sons, L.L.C.1$69
Merz Pharmaceuticals, LLC3$69
Livanova USA, Inc.4$64
Catalyst Pharmaceuticals, Inc.2$62
EDW Pharma, Inc.1$54
ANI Pharmaceuticals, Inc.2$53
Arbor Pharmaceuticals, Inc.3$47
Axsome Therapeutics, Inc.2$41
Merck2$38
MDD US Operations, LLC1$21
Novocure Inc.1$17
Ironshore Pharmaceuticals Inc.1$16
Takeda Pharmaceuticals U.S.A., Inc.1$15
Sanofi1$14
Shire North American Group Inc1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,370 in reported general payments places this provider in the 75th percentile of 474 neurology providers in Virginia.

See all neurology providers in Virginia

Medicare billing

Part B allowed, 2024
$226,452
Medicare patients
674
Services billed
3,436

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TysabriNatalizumab12$98,228
QuliptaAtogepant79$90,554
Nurtec OdtRimegepant Sulfate18$33,024
AptiomEslicarbazepine Acetate16$29,796
UbrelvyUbrogepant25$28,136
Emgality PenGalcanezumab-Gnlm21$22,413
NamzaricMemantine Hcl/Donepezil Hcl16$14,053
Aimovig AutoinjectorErenumab-Aooe17$12,652
HorizantGabapentin Enacarbil12$7,554
Buprenorphine18$4,432
Lacosamide55$4,352
Carbamazepine ErCarbamazepine32$4,318
Pregabalin205$3,938
Duloxetine Hcl173$3,472
Oxcarbazepine70$3,402

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy, Namzaric$1,785$132,743120 claims
BiogenTysabri$2,258$98,22812 claims
PfizerNurtec Odt$510$33,02418 claims
Sunovion Pharmaceuticals Inc.Aptiom$667$29,79616 claims
Arbor Pharmaceuticals, Inc.Horizant$47$7,55412 claims
Upsher-smith Laboratories LLCTopiramate$150$1,944163 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 474 neurology providers in Virginia.

Other neurology in Danville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →